These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 10888616)

  • 1. Effective vaccine for lassa fever.
    Fisher-Hoch SP; Hutwagner L; Brown B; McCormick JB
    J Virol; 2000 Aug; 74(15):6777-83. PubMed ID: 10888616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus.
    Morrison HG; Bauer SP; Lange JV; Esposito JJ; McCormick JB; Auperin DD
    Virology; 1989 Jul; 171(1):179-88. PubMed ID: 2741340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys.
    McCormick JB; Mitchell SW; Kiley MP; Ruo S; Fisher-Hoch SP
    J Med Virol; 1992 May; 37(1):1-7. PubMed ID: 1619397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a new vaccine for the prevention of Lassa fever.
    Geisbert TW; Jones S; Fritz EA; Shurtleff AC; Geisbert JB; Liebscher R; Grolla A; Ströher U; Fernando L; Daddario KM; Guttieri MC; Mothé BR; Larsen T; Hensley LE; Jahrling PB; Feldmann H
    PLoS Med; 2005 Jun; 2(6):e183. PubMed ID: 15971954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene.
    Fisher-Hoch SP; McCormick JB; Auperin D; Brown BG; Castor M; Perez G; Ruo S; Conaty A; Brammer L; Bauer S
    Proc Natl Acad Sci U S A; 1989 Jan; 86(1):317-21. PubMed ID: 2911575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity.
    Zapata JC; Poonia B; Bryant J; Davis H; Ateh E; George L; Crasta O; Zhang Y; Slezak T; Jaing C; Pauza CD; Goicochea M; Moshkoff D; Lukashevich IS; Salvato MS
    Virol J; 2013 Feb; 10():52. PubMed ID: 23402317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
    Branco LM; Grove JN; Geske FJ; Boisen ML; Muncy IJ; Magliato SA; Henderson LA; Schoepp RJ; Cashman KA; Hensley LE; Garry RF
    Virol J; 2010 Oct; 7():279. PubMed ID: 20961433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.
    Cashman KA; Wilkinson ER; Wollen SE; Shamblin JD; Zelko JM; Bearss JJ; Zeng X; Broderick KE; Schmaljohn CS
    Hum Vaccin Immunother; 2017 Dec; 13(12):3010-3019. PubMed ID: 29135337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards a human Lassa fever vaccine.
    Fisher-Hoch SP; McCormick JB
    Rev Med Virol; 2001; 11(5):331-41. PubMed ID: 11590670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses.
    Marzi A; Feldmann F; Geisbert TW; Feldmann H; Safronetz D
    Emerg Infect Dis; 2015 Feb; 21(2):305-7. PubMed ID: 25625358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death.
    Cross RW; Xu R; Matassov D; Hamm S; Latham TE; Gerardi CS; Nowak RM; Geisbert JB; Ota-Setlik A; Agans KN; Luckay A; Witko SE; Soukieh L; Deer DJ; Mire CE; Feldmann H; Happi C; Fenton KA; Eldridge JH; Geisbert TW
    J Clin Invest; 2020 Jan; 130(1):539-551. PubMed ID: 31820871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques.
    Jiang J; Banglore P; Cashman KA; Schmaljohn CS; Schultheis K; Pugh H; Nguyen J; Humeau LM; Broderick KE; Ramos SJ
    Hum Vaccin Immunother; 2019; 15(9):2066-2074. PubMed ID: 31071008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A trial to produce an inactivated Lassa fever vaccine].
    Krasnianskiĭ VP; Potryvaeva NV; Borisevich IV; Gradoboev VN; Pashanina TP; Pshenichnov VA
    Vopr Virusol; 1993; 38(6):276-9. PubMed ID: 8303891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
    Hashizume M; Takashima A; Iwasaki M
    J Virol; 2024 Jun; 98(6):e0057824. PubMed ID: 38767352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
    Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection From Lethal Lassa Disease Can Be Achieved Both Before and After Virus Exposure by Administration of Single-Cycle Replicating Lassa Virus Replicon Particles.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Scholte FEM; Goldsmith CS; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2019 Sep; 220(8):1281-1289. PubMed ID: 31152662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever.
    Clegg JC; Lloyd G
    Lancet; 1987 Jul; 2(8552):186-8. PubMed ID: 2885642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.
    Carnec X; Mateo M; Page A; Reynard S; Hortion J; Picard C; Yekwa E; Barrot L; Barron S; Vallve A; Raoul H; Carbonnelle C; Ferron F; Baize S
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine platforms to control Lassa fever.
    Lukashevich IS; Pushko P
    Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.
    Cashman KA; Wilkinson ER; Shaia CI; Facemire PR; Bell TM; Bearss JJ; Shamblin JD; Wollen SE; Broderick KE; Sardesai NY; Schmaljohn CS
    Hum Vaccin Immunother; 2017 Dec; 13(12):2902-2911. PubMed ID: 29045192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.